Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
TENX logo TENX
Upturn stock ratingUpturn stock rating
TENX logo

Tenax Therapeutics Inc (TENX)

Upturn stock ratingUpturn stock rating
$5.85
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/27/2025: TENX (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.

Year Target Price $18.85

Year Target Price $18.85

Analyst’s Price TargetsFor last 52 week
$18.85Target price
Low$2.8
Current$5.85
high$7.89

Analysis of Past Performance

Type Stock
Historic Profit 3.27%
Avg. Invested days 37
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 24.27M USD
Price to earnings Ratio 3.46
1Y Target Price 18.85
Price to earnings Ratio 3.46
1Y Target Price 18.85
Volume (30-day avg) -
Beta 1.62
52 Weeks Range 2.80 - 7.89
Updated Date 06/29/2025
52 Weeks Range 2.80 - 7.89
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) 1.69

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -26.6%
Return on Equity (TTM) -39.78%

Valuation

Trailing PE 3.46
Forward PE 0.3
Enterprise Value 15163482
Price to Sales(TTM) -
Enterprise Value 15163482
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.14
Shares Outstanding 4148500
Shares Floating 4091921
Shares Outstanding 4148500
Shares Floating 4091921
Percent Insiders 0.23
Percent Institutions 66.59

Analyst Ratings

Rating 4.75
Target Price 18.85
Buy 1
Strong Buy 3
Buy 1
Strong Buy 3
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Tenax Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing products for critical care markets. Originally incorporated as Oxygen Biotherapeutics, Inc. in 2004, the company changed its name to Tenax Therapeutics, Inc. in 2014. It has focused on developing levosimendan for various indications.

business area logo Core Business Areas

  • Pharmaceutical Development: Focuses on developing and commercializing levosimendan for the treatment of pulmonary hypertension and other cardiovascular conditions.

leadership logo Leadership and Structure

The leadership team consists of key executives responsible for the company's strategy, operations, and clinical development programs. The organizational structure includes departments for research and development, clinical trials, regulatory affairs, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • Levosimendan (Istaroxime): Levosimendan is a calcium sensitizer and KATP channel opener being developed for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (HFpEF) and other cardiovascular conditions. Market share data is not publicly available as it is still in development. Competitors include companies developing treatments for pulmonary hypertension and HFpEF, such as Actelion Pharmaceuticals (now part of Johnson & Johnson) and Novartis.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive and research-intensive, with a focus on developing new therapies for unmet medical needs. The market for cardiovascular drugs is significant and growing, driven by aging populations and increasing prevalence of heart disease and pulmonary hypertension.

Positioning

Tenax Therapeutics is positioned as a company focused on developing novel therapies for critical care markets, specifically cardiovascular conditions. Its competitive advantage lies in its proprietary formulation of levosimendan and its potential to address unmet medical needs in pulmonary hypertension and HFpEF.

Total Addressable Market (TAM)

The TAM for treatments targeting pulmonary hypertension and HFpEF is estimated to be in the billions of dollars. Tenax Therapeutics is positioned to capture a portion of this market with successful development and commercialization of levosimendan.

Upturn SWOT Analysis

Strengths

  • Proprietary formulation of levosimendan
  • Focus on unmet medical needs in cardiovascular conditions
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Dependence on successful clinical trial outcomes
  • High regulatory hurdles

Opportunities

  • Potential for breakthrough therapy designation
  • Strategic partnerships with larger pharmaceutical companies
  • Expansion into new indications

Threats

  • Competition from established pharmaceutical companies
  • Failure to obtain regulatory approval
  • Unfavorable clinical trial results

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • NVS
  • MRK

Competitive Landscape

Tenax Therapeutics faces significant competition from established pharmaceutical companies with greater resources and established products. Its competitive advantage lies in its proprietary formulation of levosimendan and its focus on unmet medical needs.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to the company's development stage.

Future Projections: Future growth depends on the successful development and commercialization of levosimendan and other potential therapies.

Recent Initiatives: Recent initiatives include clinical trials for levosimendan in pulmonary hypertension and HFpEF and securing funding for research and development activities.

Summary

Tenax Therapeutics is a development-stage pharmaceutical company focused on cardiovascular conditions, particularly pulmonary hypertension. Its future success hinges on the positive outcomes of its clinical trials and subsequent regulatory approvals for levosimendan. The company operates in a competitive market and faces challenges related to financial resources and regulatory hurdles. Successful commercialization could lead to significant growth, but risks remain high.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings (SEC)
  • Press releases
  • Analyst reports
  • Company website

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be complete or accurate. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Tenax Therapeutics Inc

Exchange NASDAQ
Headquaters Chapel Hill, NC, United States
IPO Launch date 1997-01-02
CEO, President & Director Mr. Christopher T. Giordano
Sector Healthcare
Industry Biotechnology
Full time employees 4
Full time employees 4

Tenax Therapeutics, Inc., a clinical-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.